Skip to content
HOMETECH DIRECTORYNEWS & DEVELOPMENTSRELOCATEEMPLOYERSNEIGHBORHOODSABOUTSchedule a Call

Strata Oncology: The Ann Arbor Precision Oncology Network That Raised $90M

Strata Oncology runs a precision oncology network across health systems and pharma. Founded by Dan Rhodes and Scott Tomlins out of U-M. $90M raised in J...

A2Hub Editorial· Rusty Roof Media· Updated May 4, 2026

Strata Oncology

By A2Hub Editorial. Published 2026-04-22. Last updated: 2026-04-22.

At a glance

  • Founded: 2015
  • Founders: Dan Rhodes (CEO), Scott Tomlins (chief medical officer, U-M pathologist), Keith Flaherty (oncologist, MGH)
  • HQ: Ann Arbor, Michigan
  • Funding raised: $90M latest round in July 2021, on top of earlier rounds
  • Flagship products: StrataNGS tumor sequencing, Strata Select therapy matching
  • Status: Private, commercial-stage
  • Website: strataoncology.com

The pitch in one line

Strata Oncology is the precision oncology network that bridges hospital tumor boards and pharmaceutical clinical trials. The Ann Arbor team built a tumor sequencing test, embedded it inside a network of health systems, and turned the resulting molecular data into a precision oncology platform that pharma uses for trial enrollment and biomarker work.

Founding story: pathology, oncology, and the Strata network

Strata Oncology was founded in 2015 by Dan Rhodes (CEO), Scott Tomlins (a University of Michigan-trained pathologist who serves as chief medical officer), and Keith Flaherty (an oncologist at Massachusetts General Hospital). All three came out of academic precision oncology programs that had spent the late 2000s and early 2010s establishing that tumor genetic profiling could match patients to targeted therapies more effectively than histology-based diagnosis alone.

The thesis was network-shaped. Most precision oncology testing companies of the early 2010s had built lab businesses: send your tumor sample to the lab, get a sequencing report back, end of relationship. Strata's bet was that the testing was the wedge, but the durable business was the network. If you could persuade a coalition of health systems to use the same sequencing test on their oncology patients, you could aggregate the resulting molecular data into a network that pharmaceutical companies would pay to access for clinical trial enrollment, biomarker validation, and real-world evidence.

That bet has played out. Strata's network of partner health systems has grown into one of the larger US precision oncology networks. The pharma customer base for trial enrollment and biomarker work has scaled in parallel.

What they build

Strata's product set spans clinical testing, network-driven trial enrollment, and pharmaceutical services.

StrataNGS. The proprietary tumor sequencing test. StrataNGS is the entry point for the network model; partner health systems use it on their oncology patients, generating both clinical reports and the molecular dataset that powers the network.

Strata Select. A therapy-matching service that helps oncologists identify FDA-approved therapies and clinical trials matched to a patient's tumor profile.

Pharma trial enrollment. Pharma customers contract with Strata to use the network for clinical trial enrollment, particularly for trials that require rare molecular subtypes that no single health system could enroll alone.

Real-world evidence and biomarker work. Pharma customers use the molecular and clinical data aggregated through the network for biomarker validation, label expansion, and post-market evidence.

The dual customer model (health systems on the network side, pharma on the data and enrollment side) is the company's distinguishing strategic position. It is harder to assemble than a pure lab business, but once assembled it produces a defensible asset that competitors cannot easily replicate.

Funding history

Strata Oncology raised a $90M round in July 2021, the most prominent of several rounds across the company's history. The investor base has spanned biotech-focused growth funds and strategic investors interested in the precision oncology category. Total funding to date is in the range of well over $100M when prior rounds are included.

The capital base has supported both the lab operations of StrataNGS (which require ongoing investment in CLIA-certified lab capacity, regulatory compliance, and reimbursement work) and the network-and-platform side of the business.

Ann Arbor footprint

Strata Oncology is headquartered in Ann Arbor and operates a team that spans clinical lab operations, computational biology, software engineering, commercial and pharma partnership staff. The U-M connection through Scott Tomlins remains direct; the company has been a recurring destination for U-M pathology, computational biology, and oncology talent.

The Ann Arbor location is consistent with the broader Michigan precision medicine cluster: U-M's Rogel Cancer Center, the Michigan Medicine genomics infrastructure, and the broader clinical research footprint of Michigan Medicine. Strata sits inside that cluster as one of the companies converting academic precision oncology research into a commercial network.

Leadership and people

Dan Rhodes has been CEO across the company's history. Scott Tomlins remains chief medical officer and is the public face of the company's clinical and scientific work. Keith Flaherty's involvement has positioned Strata across the Ann Arbor / Boston axis of academic oncology, which has been useful for recruiting both scientific advisors and pharmaceutical partners.

The broader executive bench has been built from a mix of biopharma services operators, clinical lab leadership, and pharmaceutical partnership executives. The senior team's pharma-side experience is part of why Strata has been able to scale the pharmaceutical revenue line alongside the network growth; pharmaceutical partnership business development is a different muscle from clinical lab operations, and the company has built bench depth on both sides of the business.

Strata's network of partner health systems implies an additional layer of de facto leadership across the partner sites. Each partner system has clinical and operational leaders who serve on Strata's network advisory structure; that distributed governance is part of what holds the network together as it grows.

Why it matters

Three reasons Strata Oncology matters in the Ann Arbor story.

First, it is one of the larger commercially active precision oncology companies operating from Ann Arbor. The Michigan precision medicine cluster (Strata, Genomenon, ArborMetrix, HistoSonics, Esperion) is one of the city's most credible biotech bench positions, and Strata is one of the anchors.

Second, the network model is strategically distinctive. Most precision oncology testing companies have been pure lab businesses. Strata's combination of testing plus health-system network plus pharma data partnership is harder to replicate and produces a more defensible long-term position.

Third, the U-M pathology lineage matters. Scott Tomlins' work in academic pathology and the broader U-M precision oncology research community provides the scientific credibility that has been part of Strata's pharma partnership story. That kind of academic-to-commercial bridge is exactly the playbook that the University of Michigan tech startups ecosystem has been built to enable.

Related

  • Genomenon is the Ann Arbor genomic search engine company whose customer base overlaps with Strata's pharma and lab footprint.
  • ArborMetrix is the Ann Arbor real-world data company that shares the broader Michigan health-data cluster.
  • Akadeum Life Sciences is the Ann Arbor cell separation company in the broader precision medicine bench.
  • The biotech category hub covers the full Ann Arbor biotech bench.
  • The companies directory is the master index.

FAQ

Where is Strata Oncology headquartered? Strata Oncology is headquartered in Ann Arbor, Michigan.

Who founded Strata Oncology? Strata Oncology was founded in 2015 by Dan Rhodes (CEO), Scott Tomlins (chief medical officer, U-M pathology), and Keith Flaherty (Massachusetts General Hospital oncology).

What does Strata Oncology do? Strata Oncology runs a precision oncology network that combines tumor sequencing (StrataNGS), therapy and trial matching (Strata Select), and pharmaceutical services for clinical trial enrollment and biomarker work. Partner health systems use the testing on oncology patients; pharma customers contract for network access for trial enrollment and real-world evidence.

How much funding has Strata Oncology raised? Strata raised a $90M round in July 2021, on top of earlier rounds. Total funding is in the range of well over $100M when prior rounds are included.

Who are Strata Oncology's customers? The customer model is dual-sided. Partner health systems use StrataNGS on oncology patients. Pharmaceutical customers contract for network access for clinical trial enrollment, biomarker validation, and real-world evidence.

How does Strata differ from other precision oncology companies? Most precision oncology testing companies operate as pure lab businesses. Strata's distinguishing model combines the testing wedge with a health-system network and a pharma data and enrollment business, which produces a more defensible network asset over time.

Is Strata Oncology hiring? Yes. Open roles in clinical laboratory operations, bioinformatics, software engineering, clinical-trial operations, medical affairs, and commercial functions are posted at strataoncology.com/careers. The work model is hybrid with meaningful on-site requirements for laboratory staff.

Strategic reading

The precision oncology category has been one of the most active subsegments of healthcare in the past decade, and the competitive set is serious. Tempus AI (now publicly listed) and Caris Life Sciences are the largest US precision oncology companies by revenue, with lab-and-data businesses in the hundreds of millions of dollars annually. Natera, Guardant Health, and Foundation Medicine (Roche-owned) round out the larger commercial players, each with distinct subsegment positioning. Strata's dollar scale is smaller than these competitors, but its network-first model and community-setting depth gives it a differentiated positioning that the larger pure-lab businesses have had difficulty replicating.

Strategic considerations to watch. First, the pharma spend environment for biomarker-driven trials. Precision oncology spending has been one of the stronger pharma R&D categories through the last five years, but it is sensitive to broader pharma capital cycles. Second, the evolution of tumor-agnostic therapy approvals (drugs approved based on molecular features rather than tumor type) expands the clinical case for universal tumor profiling and therefore the demand for networks like Strata. Third, the reimbursement environment for comprehensive genomic profiling remains complex and is a continuous operating challenge for every lab in the category.

Bull case: Strata's network effects compound as more health systems join, more trials route through the network, and more pharma relationships deepen. Bear case: larger competitors (Tempus, Caris) or consolidators (a pharma-services roll-up, a diagnostics platform) pursue similar community-setting network strategies at greater capital scale, and Strata's window to scale independently closes.